Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan

PHASE3CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 5, 2018

Primary Completion Date

December 3, 2018

Study Completion Date

December 17, 2018

Conditions
Anemia; Hemodialysis Dependent Chronic Kidney Disease
Interventions
DRUG

MT-6548

Oral tablet

Trial Locations (16)

Unknown

Research site, Aichi

Research site, Chiba

Research site, Fukushima

Research site, Gunma

Research site, Hokkaido

Research site, Hyōgo

Research site, Ibaraki

Research site, Kagoshima

Research site, Nagano

Research site, Okayama

Research site, Okinawa

Research site, Osaka

Research site, Saitama

Research site, Shiga

Research site, Shizuoka

Research site, Yamagata

All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY